Published in J Pharmacol Exp Ther on March 26, 2003
Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther (2008) 1.42
Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J (2010) 1.10
Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res (2010) 1.01
Profiling of drugs and environmental chemicals for functional impairment of neural crest migration in a novel stem cell-based test battery. Arch Toxicol (2014) 0.99
Interferon-beta 1a and SARS coronavirus replication. Emerg Infect Dis (2004) 0.95
Interspecies modeling and prediction of human exenatide pharmacokinetics. Pharm Res (2012) 0.89
Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study. Br J Clin Pharmacol (2015) 0.85
A Tutorial on Target-Mediated Drug Disposition (TMDD) Models. CPT Pharmacometrics Syst Pharmacol (2015) 0.83
Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in mice. J Pharmacol Exp Ther (2010) 0.79
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. MAbs (2015) 0.78
Quantitative measurement of the target-mediated internalization kinetics of biopharmaceuticals. Pharm Res (2014) 0.78
Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents. CPT Pharmacometrics Syst Pharmacol (2013) 0.77
Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology. Drug Metab Dispos (2011) 0.77
Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies. AAPS J (2013) 0.77
Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition. J Pharmacokinet Pharmacodyn (2010) 0.76
Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeutics. J Pharm Sci (2014) 0.75
Is it time to consider rationalizing IFN-beta treatment in individuals with multiple sclerosis? J Neurol Neurosurg Psychiatry (2004) 0.75
Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats. Pharm Res (2014) 0.75
Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos (2003) 1.93
Modeling of corticosteroid pharmacogenomics in rat liver using gene microarrays. J Pharmacol Exp Ther (2003) 1.71
Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol (2004) 1.45
Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother (2010) 1.44
Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet (2008) 1.44
The PEPR GeneChip data warehouse, and implementation of a dynamic time series query tool (SGQT) with graphical interface. Nucleic Acids Res (2004) 1.40
Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J Pharmacokinet Pharmacodyn (2002) 1.40
Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer (2009) 1.39
Pharmacodynamics and pharmacogenomics of methylprednisolone during 7-day infusions in rats. J Pharmacol Exp Ther (2002) 1.36
Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos (2006) 1.33
Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother (2008) 1.26
Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans. J Pharmacokinet Pharmacodyn (2006) 1.20
Gene expression analysis of hepatic roles in cause and development of diabetes in Goto-Kakizaki rats. J Endocrinol (2008) 1.18
Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet (2009) 1.17
Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats. J Pharmacol Exp Ther (2008) 1.16
Gene arrays and temporal patterns of drug response: corticosteroid effects on rat liver. Funct Integr Genomics (2003) 1.16
Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol (2003) 1.16
Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci (2005) 1.16
Corticosteroid-regulated genes in rat kidney: mining time series array data. Am J Physiol Endocrinol Metab (2005) 1.14
Pharmacogenomic responses of rat liver to methylprednisolone: an approach to mining a rich microarray time series. AAPS J (2005) 1.11
Modeling circadian rhythms of glucocorticoid receptor and glutamine synthetase expression in rat skeletal muscle. Pharm Res (2006) 1.10
Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev (2010) 1.10
Microarray analysis of the temporal response of skeletal muscle to methylprednisolone: comparative analysis of two dosing regimens. Physiol Genomics (2007) 1.10
Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin. Br J Clin Pharmacol (2005) 1.09
Pharmacodynamic interaction of recombinant human interleukin-10 and prednisolone using in vitro whole blood lymphocyte proliferation. J Pharm Sci (2002) 1.09
Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos (2007) 1.09
Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn (2007) 1.08
Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. J Pharmacol Exp Ther (2006) 1.06
In vivo multi-tissue corticosteroid microarray time series available online at Public Expression Profile Resource (PEPR). Pharmacogenomics (2003) 1.06
Circadian variations in rat liver gene expression: relationships to drug actions. J Pharmacol Exp Ther (2008) 1.05
The genomic response of skeletal muscle to methylprednisolone using microarrays: tailoring data mining to the structure of the pharmacogenomic time series. Pharmacogenomics (2004) 1.05
Utility of cleavable isotope-coded affinity-tagged reagents for quantification of low-copy proteins induced by methylprednisolone using liquid chromatography/tandem mass spectrometry. Anal Chem (2006) 1.05
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemother Pharmacol (2008) 1.05
Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. J Pharmacol Exp Ther (2003) 1.04
Methods of utilizing baseline values for indirect response models. J Pharmacokinet Pharmacodyn (2009) 1.03
Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans. Pharm Res (2002) 1.03
A microarray analysis of the temporal response of liver to methylprednisolone: a comparative analysis of two dosing regimens. Endocrinology (2007) 1.03
Receptor/gene-mediated pharmacodynamic effects of methylprednisolone on phosphoenolpyruvate carboxykinase regulation in rat liver. J Pharmacol Exp Ther (2004) 1.02
Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. J Pharmacol Exp Ther (2010) 1.02
Area/moment and compartmental modeling of pharmacokinetics during pregnancy: applications to maternal/fetal exposures to corticosteroids in sheep and rats. Pharm Res (2004) 1.01
Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. Drug Metab Dispos (2012) 1.00
Modeling the metabolic effects of terbutaline in beta2-adrenergic receptor diplotypes. Clin Pharmacol Ther (2004) 1.00
Temporal profiling of the transcriptional basis for the development of corticosteroid-induced insulin resistance in rat muscle. J Endocrinol (2005) 1.00
Adipose tissue deficiency and chronic inflammation in diabetic Goto-Kakizaki rats. PLoS One (2011) 0.99
Stabilization and HPLC analysis of betamethasone sodium phosphate in plasma. J Pharm Sci (2004) 0.99
Comparison of dexamethasone pharmacokinetics in female rats after intravenous and intramuscular administration. Biopharm Drug Dispos (2005) 0.99
Modeling of corticosteroid effects on hepatic low-density lipoprotein receptors and plasma lipid dynamics in rats. Pharm Res (2007) 0.98
Relationships between circadian rhythms and modulation of gene expression by glucocorticoids in skeletal muscle. Am J Physiol Regul Integr Comp Physiol (2008) 0.98
Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn (2013) 0.98
Integrated QSPR--pharmacodynamic model of genomic effects of several corticosteroids. J Pharm Sci (2003) 0.98
Modeling corticosteroid effects in a rat model of rheumatoid arthritis II: mechanistic pharmacodynamic model for dexamethasone effects in Lewis rats with collagen-induced arthritis. J Pharmacol Exp Ther (2008) 0.98
Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn (2012) 0.97
Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. J Clin Pharmacol (2010) 0.96
Modeling diabetes disease progression and salsalate intervention in Goto-Kakizaki rats. J Pharmacol Exp Ther (2011) 0.96
Assessment of drug interactions relevant to pharmacodynamic indirect response models. J Pharmacokinet Pharmacodyn (2004) 0.96
Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation. Br J Clin Pharmacol (2002) 0.96
Betamethasone pharmacokinetics after two prodrug formulations in sheep: implications for antenatal corticosteroid use. Drug Metab Dispos (2005) 0.95
Pharmacodynamics and pharmacogenomics of diverse receptor-mediated effects of methylprednisolone in rats using microarray analysis. J Pharmacokinet Pharmacodyn (2002) 0.94
Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity--pharmacodynamic drug-drug interaction modeling. Clin Cancer Res (2007) 0.94
Modeling receptor/gene-mediated effects of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by endogenous and exogenous corticosteroids. J Pharmacokinet Pharmacodyn (2007) 0.93
Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn (2014) 0.93
Mechanism-based modeling of nutritional and leptin influences on growth in normal and type 2 diabetic rats. J Pharmacol Exp Ther (2008) 0.93
Circadian variations in gene expression in rat abdominal adipose tissue and relationship to physiology. Physiol Genomics (2010) 0.93
Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chemother Pharmacol (2007) 0.93
Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models. J Pharmacokinet Pharmacodyn (2006) 0.92
Modeling glucocorticoid-mediated fetal lung maturation: I. Temporal patterns of corticosteroids in rat pregnancy. J Pharmacol Exp Ther (2005) 0.92
The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy (2004) 0.91
Multiple-pool cell lifespan model of hematologic effects of anticancer agents. J Pharmacokinet Pharmacodyn (2002) 0.91
Population cell life span models for effects of drugs following indirect mechanisms of action. J Pharmacokinet Pharmacodyn (2005) 0.91
Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritis. Pharm Res (2011) 0.90
Mechanism-based disease progression modeling of type 2 diabetes in Goto-Kakizaki rats. J Pharmacokinet Pharmacodyn (2010) 0.90
Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers. J Clin Pharmacol (2007) 0.90
Differential muscle gene expression as a function of disease progression in Goto-Kakizaki diabetic rats. Mol Cell Endocrinol (2011) 0.90
Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity. Cancer Chemother Pharmacol (2009) 0.90
Assessment of basic indirect pharmacodynamic response models with physiological limits. J Pharmacokinet Pharmacodyn (2006) 0.89
Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. J Pharm Sci (2002) 0.89
Pharmacokinetic/pharmacodynamic modeling of glucose clamp effects of inhaled and subcutaneous insulin in healthy volunteers and diabetic patients. Drug Metab Pharmacokinet (2010) 0.89
Stability of dexamethasone sodium phosphate in rat plasma. Int J Pharm (2005) 0.89
Assessing the dynamics of nuclear glucocorticoid-receptor complex: adding flexibility to gene expression modeling. J Pharmacokinet Pharmacodyn (2007) 0.89
Quantitative dynamic models of arthritis progression in the rat. Pharm Res (2008) 0.89
Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol (2008) 0.88
Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin Pharmacol Ther (2002) 0.88
Mathematical modeling of corticosteroid pharmacogenomics in rat muscle following acute and chronic methylprednisolone dosing. Mol Pharm (2008) 0.87
Importance of replication in analyzing time-series gene expression data: corticosteroid dynamics and circadian patterns in rat liver. BMC Bioinformatics (2010) 0.87
Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis. J Pharmacokinet Pharmacodyn (2011) 0.87
Pharmacodynamics of glucose regulation by methylprednisolone. I. Adrenalectomized rats. Biopharm Drug Dispos (2009) 0.87
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother Pharmacol (2008) 0.87
Pharmacodynamics of glucose regulation by methylprednisolone. II. normal rats. Biopharm Drug Dispos (2009) 0.87
Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. Br J Clin Pharmacol (2012) 0.86
Light-dark oscillations in the lung transcriptome: implications for lung homeostasis, repair, metabolism, disease, and drug action. J Appl Physiol (1985) (2011) 0.86
Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells. Cancer Chemother Pharmacol (2013) 0.86
Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. J Clin Pharmacol (2003) 0.86
Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop. AAPS J (2011) 0.85
Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs. J Clin Pharmacol (2008) 0.85
Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus. J Clin Pharmacol (2009) 0.85
Evidence for a glucocorticoid receptor beta splice variant in the rat and its physiological regulation in liver. Steroids (2012) 0.85
Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats. Biopharm Drug Dispos (2007) 0.85
Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats. J Pharm Sci (2008) 0.85
Kinetics of betamethasone and fetal cardiovascular adverse effects in pregnant sheep after different doses. Obstet Gynecol (2006) 0.85
Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats. J Pharmacol Exp Ther (2012) 0.84